Berger, A.E.; Gleizes, A.; Waeckel, L.; Roblin, X.; Krzysiek, R.; Hacein-Bey-Abina, S.; Soriano, A.; Paul, S.
Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10® to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies. Int. J. Mol. Sci. 2022, 23, 9561.
https://doi.org/10.3390/ijms23179561
AMA Style
Berger AE, Gleizes A, Waeckel L, Roblin X, Krzysiek R, Hacein-Bey-Abina S, Soriano A, Paul S.
Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10® to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies. International Journal of Molecular Sciences. 2022; 23(17):9561.
https://doi.org/10.3390/ijms23179561
Chicago/Turabian Style
Berger, Anne Emmanuelle, Aude Gleizes, Louis Waeckel, Xavier Roblin, Roman Krzysiek, Salima Hacein-Bey-Abina, Alessandra Soriano, and Stephane Paul.
2022. "Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10® to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies" International Journal of Molecular Sciences 23, no. 17: 9561.
https://doi.org/10.3390/ijms23179561
APA Style
Berger, A. E., Gleizes, A., Waeckel, L., Roblin, X., Krzysiek, R., Hacein-Bey-Abina, S., Soriano, A., & Paul, S.
(2022). Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10® to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies. International Journal of Molecular Sciences, 23(17), 9561.
https://doi.org/10.3390/ijms23179561